Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
- Conditions
- Interventions
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00126672
- Locations
- 🇺🇸
New York University Medical Center, New York, New York, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 305
- Registration Number
- NCT00121810
Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
- Conditions
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2010-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 293
- Registration Number
- NCT00118742
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
- Conditions
- Previously Treated Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveWaldenstrom MacroglobulinemiaChildhood Myelodysplastic SyndromeStage II Contiguous Adult Diffuse Large Cell LymphomaStage II Contiguous Adult Lymphoblastic LymphomaStage II Grade 1 Contiguous Follicular LymphomaStage II Grade 2 Contiguous Follicular LymphomaStage II Non-Contiguous Adult Burkitt Lymphoma
- Interventions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 210
- Registration Number
- NCT00105001
- Locations
- 🇩🇰
Rigshospitalet University Hospital, Copenhagen, Denmark
🇺🇸Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇩🇪Medizinische Univ Klinik Koln, Koln, Germany
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00098462
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
- Conditions
- Interventions
- First Posted Date
- 2004-09-22
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 75
- Registration Number
- NCT00092222
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
- Conditions
- First Posted Date
- 2004-09-02
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00002790
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2011-07-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00089037
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT00079183
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
- Conditions
- Interventions
- First Posted Date
- 2004-03-02
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 10
- Registration Number
- NCT00078559
- Locations
- 🇺🇸
University of Wisconsin - Department of Medicine, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.